中证沪港深创新药产业指数上涨4.03%

Core Viewpoint - The SHS Innovation Drug Index has shown significant growth, reflecting the performance of listed companies involved in innovative drug research and production in both mainland China and Hong Kong [1]. Group 1: Index Performance - The SHS Innovation Drug Index increased by 4.03%, reaching 2393.56 points, with a trading volume of 54.435 billion [1]. - Over the past month, the index has risen by 11.98%, and over the last three months, it has increased by 35.45%. Year-to-date, the index has surged by 47.88% [1]. Group 2: Index Composition and Adjustments - The index is composed of up to 50 representative securities selected from mainland and Hong Kong markets, focusing on companies engaged in innovative drug development and production [1]. - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year. Weight factors are generally fixed until the next adjustment [1]. - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [1].